Breast Reduction Clinical Trial
Official title:
Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride for Postoperative Analgesia After Breast Reduction Surgery: A Prospective, Single Blind, Non-randomized Controlled Trial
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
This is a prospective, multi-surgeon, single blind, non-randomized, controlled trial with breasts allocated to two parallel groups: A mixture of liposomal (Exparel) bupivacaine with plain 0.25% bupivacaine hydrochloride will be used on one side (Treatment side) as local infiltration, and plain 0.25% Bupivacaine Hydrochloride will be used in the control arm. Each breast will serve as the control for the other. The study is designed to evaluate early postoperative pain control of each of the products up to 72 hours postoperatively. These treatments are standard of care in clinical practice. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03280043 -
Risk of Hematoma After Ketorolac Use in Reduction Mammoplasty.
|
N/A | |
| Completed |
NCT04439396 -
Toradol (Ketorolac) in Breast Surgery to Reduce Pain & Opioid Use
|
Phase 1 | |
| Completed |
NCT00605670 -
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery
|
N/A | |
| Recruiting |
NCT05822115 -
Reduction of Breast Hypertrophy by Means of Coelioscopique Surgery
|
N/A |